869 related articles for article (PubMed ID: 18162040)
1. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
Fu X; Rivera A; Tao L; Zhang X
Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
5. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
6. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
9. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
[TBL] [Abstract][Full Text] [Related]
10. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
11. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
Puhlmann M; Brown CK; Gnant M; Huang J; Libutti SK; Alexander HR; Bartlett DL
Cancer Gene Ther; 2000 Jan; 7(1):66-73. PubMed ID: 10678358
[TBL] [Abstract][Full Text] [Related]
12. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
13. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes.
Cho E; Islam SMBU; Jiang F; Park JE; Lee B; Kim ND; Hwang TH
Cancer Res Treat; 2020 Jan; 52(1):309-319. PubMed ID: 31401821
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.
Fend L; Yamazaki T; Remy C; Fahrner C; Gantzer M; Nourtier V; Préville X; Quéméneur E; Kepp O; Adam J; Marabelle A; Pitt JM; Kroemer G; Zitvogel L
Cancer Res; 2017 Aug; 77(15):4146-4157. PubMed ID: 28536278
[TBL] [Abstract][Full Text] [Related]
16. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
17. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE; Ilett EJ; Melcher AA
Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
[TBL] [Abstract][Full Text] [Related]
18. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
[TBL] [Abstract][Full Text] [Related]
19. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
20. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.
Kim EJ; Yoo JY; Choi YH; Ahn KJ; Lee JD; Yun CO; Yun M
Yonsei Med J; 2008 Oct; 49(5):811-8. PubMed ID: 18972602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
